BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mauna Kea Technologies Announces the Publication of World's First Direct Visualization of the Digestive Tract's Nervous System


11/27/2012 11:05:40 AM

PARIS--(Marketwire - November 27, 2012) - Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, today announced that gastroenterologists in Japan and Germany have used Cellvizio to directly view the enteric nervous system of the digestive tract during an endoscopy procedure for the first time. This study opens the door to applying optical biopsies to improve how physicians diagnose and treat functional gastrointestinal (GI) and motility disorders, the most common digestive disorders affecting the general population.

These findings were recently published online in the medical journal, Gastroenterology, the leading journal in the digestive field.

"The enteric nervous system controls the digestion process and operates independently from the human body's central nervous system linked to the brain and spine," said Prof. Ralf Kiesslich, M.D., head of the interdisciplinary endoscopic unit at Johannes Gutenberg University Mainz, in Mainz, Germany. "Functional GI and motility disorders like dyspepsia, irritable bowel syndrome (IBS), GERD and chronic constipation are associated with changes in the neurons and function of glial cells in the enteric nervous system. The ability to see the framework of the digestive tract's nervous system during an endoscopy should yield incredibly important information that could have a deep impact on the diagnosis and treatment of some of the most common diseases in the world."

The enteric nervous system resides in the submucosal layer of the GI tract. Investigators tested endomicroscopic imaging after they removed a tumor from a patient's colon. Endomicroscopy allowed investigators to see single muscle fibers, glial cells, neurons and the neuronal network.

"This exciting research out of Germany and Japan extends Cellvizio's value as a tool to bring a new dimension to visualization and knowledge of the GI system," said Sacha Loiseau, founder and Chief Executive of Mauna Kea Technologies. "For years, clinicians focused on pre-cancerous and cancerous conditions when using Cellvizio. Now they can explore functional and chronic diseases. The GI nervous system is often referred to as our 'second brain.' Any improvement on the management of patients with diseases with such high prevalence and tremendous detrimental impact on patients' lives will be a game changer for patients and physicians."

According to the International Foundation for Functional Gastrointestinal Disorders (IFFGD), about one in four people in the U.S. have some activity limitation of daily function due to these disorders. The conditions account for about 41% of digestive problems seen by doctors and therapists. People being treated for functional GI and motility disorders have lower quality-of-life scores -- the measure of physical, social, and emotional wellbeing -- than population norms, and those with other chronic illnesses, the IFFGD says.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, biliary and pancreatic ducts and lungs.

For more information on Mauna Kea Technologies, visit www.maunakeatech.com


United States

Lazar Partners Ltd.
Erich Sandoval
Tel: +1 917 497 2867
esandoval@lazarpartners.com

Mauna Kea Technologies
Alexander Bryson
Marketing Communications and Brand Manager
Tel: +33 (0) 1 70 08 09 92
alexander@maunakeatech.com

France et Europe

ALIZE RP
Caroline Carmagnol
Tel: +33 (0)1 42 68 86 43 / +33 (0)6 64 18 99 59
caroline@alizerp.com

NewCap.
Investor Relations and Financial Communications
Pierre Laurent / Florent Alba
Tel: +33(0)1 44 71 94 94
maunakea@newcap.fr



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES